Slide 1: Company Presentation
COMPANY PRESENTATION March 2013 Page 1
Slide 2: Forward Looking Statement
Forward Looking Statement • This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. • This document contains forward-looking statem
Slide 3: Innate Pharma at a glance
Innate Pharma at a glance • Founded in 1999 • Based in Marseilles, France – 82 employees • First-in-class immunotherapy drug candidates • Validating partnerships for clinical programs Antibodies modulating o Novo Nordisk A/S in inflammation innate immunity o Bristol-Myers Squibb in cancer against ca
Slide 4: Investment Highlights
Investment Highlights Approach validated by recent successes from industry leaders • Experienced management team • Yervoy® (BMS), first approved immunomodulating mAb in melanoma (2011) – 2012 sales of $706m • Nivolumab (anti-PD-1, BMS), in Phase III trials in NSCLC and RCC after promising Phase I da
Slide 5: Innate and Adaptive Immunity
Innate and Adaptive Immunity A cooperative system Innate immunity Adaptive immunity CD8 Activating Receptors DIRECT KILLING Stressed CD8 (NCRs, NKG2D, 92 TCR,…) or Inhibitory Receptors transformed (KIR, NKG2A, …) cell Immune CD8 ADCC memory CD16 Killer cells NK, T cells CD4 B cells CD4 IMMUNE R
Slide 6: Checkpoints of adaptive immunity
Checkpoints of adaptive immunity An increasingly crowded area Immune cell (immune checkpoints) APC or Tumor cell (tumor antigens) AZN (I&I,PhI) ICOS B7-H2 Amgen/AZN (I&I,PhI) Immutep (Onco, PhII) BMS (Onco, Preclin) LAG-3 Immutep/GSK (I&I, Preclin) TCR MHC BMS (Transplant and I&I, Marketed) Astellas
Slide 7: Innate immunity is still an open field
Innate immunity is still an open field Innate Pharma leading the field Immune cell (immune checkpoints) Tumor cell (tumor antigens) GSK/Dynavax (I&I,Preclin) TLR7/9 Idera (I&I,Preclin) Pathogens J&J (I&I,PhI) TLR3 Inflamed necrotic tissue Innate Pharma (I&I, Preclin) NKp44 ? Innate Pharma (Research)
Slide 8: Innate Pharma's pipeline
Innate Pharma’s pipeline MOLECULAR PROGRAM INDICATION STATUS PARTNER NEXT MILESTONE TARGET Acute Myeloid Leukemia Phase II Lirilumab Solid tumors, in comb. Phase I (IPH2102/ KIR2DL1,2,3 with ipilimumab Bristol‐Myers Squibb Results BMS‐986015) Solid tumors, in comb. Phase I with nivolumab IPH2201/ Rh
Slide 9: Collaborations
Innate’s approach to value creation Immunopharmacology specialist Early clinical Target sourcing Drug candidate Later development development Trial design & management Innate Pharma Antibody engineering Target validation with clinical samples Immunopharmacology up to randomized Phase II and biologic
Slide 10: Business Model
Business Model > Integrate development chain to increase product value to Innate Pharma > Build proprietary • Retain marketing rights for appropriate products antibody • Retain development rights in appropriate indications technology platform • Implement internal > Advance and broaden portfolio of h
Slide 11: Lirilumab
Lirilumab licensed to Bristol-Myers Squibb Anti-KIR mAb, first-in-class NK cell modulator, developed in cancer Page 11
Slide 12: $465 million deal with Bristol-Myers Squibb
$465 million deal with Bristol-Myers Squibb Deal watch: Bristol-Myers Squibb invests in cancer antibody that targets the innate immune system • Largest license agreement for a French biotech at signing: Bristol-Myers Squibb has acquired exclusive global rights to Innate Pharma's cancer candidate IPH
Slide 13: Activating Natural Killer cells as a therapeutic strategy
Activating Natural Killer cells as a therapeutic strategy • Lirilumab (IPH2102/BMS-986015) is a fully human mAb that blocks KIR2DL1/2/3 (“KIR”) receptors to potentiate the patient’s natural killer (NK) cells to attack tumors > NK cells are the body’s first line of defense against cancer > Cancer cel
Slide 14: Therapeutic potential of NK cells
Therapeutic potential of NK cells • NK cell activation shown to bring clear clinical benefit in bone marrow allografts in Acute Myeloid Leukemia patients > KIR-ligand incompatibility > Also seen in other hematological malignancies including multiple myeloma • NK activation results in increase in gra
Slide 15: A new mechanism of action
A new mechanism of action • Potentiating NK cells activation by blocking inhibitory receptors KIR > Survival Advantage with KIR-ligand mismatch in bone marrow transplantation from allogenic donors NK cell from donor Tumor cell from transplanted patient Mimicking NK cell activation in bone KIR-ligand
Slide 16: Phase I in AML with IPH2101
Phase I in AML with IPH2101 Hybridoma anti-KIR mAb • Elderly AML patients in complete remission after induction and consolidation treatment - maintenance setting > 23 patients, 7 dose levels (0.0003 to 3 mg/kg, 3 patients/level), single dose administration > Good tolerance with mild and transient ad
Slide 17: EffiKIR positioning in Acute Myeloid Leukemia
EffiKIR positioning in Acute Myeloid Leukemia Strong medical need for elderly patients • 5-year survival rate in elderly patients Treatment paradigm with AML is 5 to 15% Patients <60y (<50%) Patients >60y (>50%) ~ 50% ~ 50% • No current standard of care for elderly patients in post-induction Inducti
Slide 18: Randomized Phase II trial in AML sponsored by Innate
Randomized Phase II trial in AML sponsored by Innate First randomized Phase II of lirilumab • EffiKIR – Efficacy anti-KIR – is a double-blind placebo-controlled randomized Phase II trial of lirilumab as maintenance treatment in elderly patients with AML in first complete remission • Run by Innate Ph
Slide 19: Phase I trial in combination with ipilimumab in solid tumors
Phase I trial in combination with ipilimumab in solid tumors • Open-label Phase I study of lirilumab in combination with ipilimumab in patients with selected advanced solid tumors • Conducted in two parts - dose escalation and cohort expansion, expected to enroll approximately 150 patients > Tumor t
Slide 20: Phase I trial in combination with nivolumab in solid tumors
Phase I trial in combination with nivolumab in solid tumors • Open-label Phase I study of lirilumab in combination with nivolumab (anti- PD1 antibody) in patients with advanced solid tumors • Conducted in two parts - dose escalation and cohort expansion, expected to enroll approximately 150 patients
Slide 21: IPH2201/NN8765
IPH2201/ NN8765 licensed to Novo Nordisk A/S First-in-class anti-NKG2A mAb, developed in inflammation and auto-immune diseases Page 21
Slide 22: IPH2201/NN8765: A first-in-class in inflammation
IPH2201/NN8765 A first-in-class in inflammation • mAb designed to block NKG2A on sub-populations of NK cells, NKT cells and a subset of T cells > NKG2A+ subset of NK cells are infiltrated in inflamed joints > Overactivated / chronically activated CD4+ cells are susceptible to lysis by these NK cells
Slide 23: IPH2201/NN8765 out licensed to Novo Nordisk A/S
IPH2201/NN8765 Out licensed to Novo Nordisk A/S • Currently in Phase I clinical trials in Rheumatoid Arthritis > Randomized, double-blind, placebo-controlled, single-dose and multiple-dose, dose- escalation Phase I, 84 patients, IV and SC routes • Decision to initiate clinical trials (February 2011)
Slide 24: Proprietary portfolio of new monoclonal antibodies
Proprietary portfolio of new monoclonal antibodies Page 24
Slide 25: IPH41: A cytotoxic mAb targeting KIR3DL2
IPH41 A cytotoxic mAb targeting KIR3DL2 • KIR3DL2 is a new, specific and highly expressed marker of Sezary syndrome (SS) and Transformed Mycosis Fungoides (TMF) o Rare and incurable cutaneous T cell lymphomas o G7 SS and TMF population: 5,000 - 7,000 patients Patients biopsies stained with Innate’s
Slide 26: IPH33: A blocking mAb targeting TLR3
IPH33 A blocking mAb targeting TLR3 • Blocking TLR3 aims at preventing inflammatory cytokine production, upstream of current treatments for inflammation Treatment Treatment Total Score of arthritic limbs Total Score of arthritic limbs o Major inducer of type I IFN 16 16 and inflammatory cytokines 12
Slide 27: Upstream proprietary pipeline
Upstream proprietary pipeline Disclosed target: NKp46 Tuning of Natural Killer Cell Reactivity by NKp46 and Helios Calibrates T Cell Responses Emilie Narni-Mancinelli, Baptiste N. Jaeger, Claire Bernat, Aurore Fenis, Sam Kung, Aude De Gassart, Sajid Mahmood, Marta Gut, Simon C. Heath, Jordi Estellé,
Slide 28: Key corporate and financial facts
Key corporate and financial facts Page 28
Slide 29: Key figures
Key figures Year ended December 31 In thousands of euros 2012 2011 Revenue from collaboration and licensing agreements 10,377 7,454 Government financing for research expenditures 3,905 4,286 Revenue and other income 14,282 11,740 Research and development expenses (13,417) (14,843) General and admini
Slide 30: Share information and shareholders
Share information and shareholders • Listed on Euronext, IPO in November 2006 • Euronext Paris: FR0010331421 – IPH • Indexes: Next Biotech / Cac Small / CAC Pharma. & Bio • 37.9m shares outstanding (as of June 30, 2012, 39.8m fully diluted) • Average volume per day since in BOY> 375,000 shares • Ana
Slide 31: Knowledgeable and highly experienced management team
Knowledgeable and highly experienced management team Hervé Brailly Marcel Rozencweig PhD, CEO Co-founder MD, Chief Medical Officer 30 years of experience in clinical Immunotech SA, Beckman-Coulter drug development Bristol-Myers Squibb François Romagné Jérôme Tiollier PhD, PhD, Chief Scientific Offic
Slide 32: First-rate governance
First-rate governance Supervisory board Scientific Advisory Board • Gilles BRISSON, Chairman of the • Bernard MALISSEN, PhD, Chairman of Supervisory Board, formerly Aventis the SAB, CNRS (Marseille/France) Pharma SA • Philip GREENBERG, M.D., University of • Irina STAATZ-GRANZER, Vice- Washington, Fr
Slide 33: Summary
Summary Funded until mid-2015 Where we are Where we are going 2012 • 2 partnerships • Conduct of randomized New Phase II trial with • Strong cash position programs lirilumab • Recognized experience • Expanded pipeline New throughout the value targets • Organic growth or by chain acquisition New • Fo
Slide 34: Expected milestones 2012/2014
Expected milestones 2012/2014 On track Program Next milestone > Launch of the IPH2102 AML Phase II trial sponsored by IPH ✓ IPH21 > BMS program roll out ✓ IPH22 > Entry in Phase II by Novo Nordisk A/S IPH41 > Development candidate qualification > Lead candidate identification ✓ IPH33 > Partnering Un
Slide 35: Appendix
innate pharma esses age 85
Slide 36: Bibliography – IPH21 / IPH22
Bibliography – IPH21 / IPH22 IPH21: • A phase I trial of the anti-KIR antibody IPH2101 in patients with relapsed/ refractory multiple myeloma, Benson et al., Blood, 2012 • A phase I trial of the anti-inhibitory KIR monoclonal antibody IPH2101 for acute myeloid leukemia (AML) in complete remission, V
Slide 37: Bibliography – IPH33 / IPH41 / NKp46
Bibliography – IPH33 / IPH41 / NKp46 IPH33: o TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events, Cavassani et al., J Exp Med, 2008 o Influenza A Virus Activates TLR3-Dependent Inflammatory and RIG-I-Dependent Antiviral Responses in Human Lung Epithelial Cells, Le Goffi
Slide 38: Investor relations
Investor relations Laure-Hélène Mercier Director, Investor relations investors@innate-pharma.com Tel: +33 (0)4 30 30 30 87 Fax: +33 (0)4 30 30 30 30 Page 38